 Urinary Bladder Neoplasms
"Urinary Bladder Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the URINARY BLADDER.
| Descriptor ID |
D001749
|
| MeSH Number(s) |
C04.588.945.947.960 C12.758.820.968 C12.777.829.813 C13.351.937.820.945 C13.351.968.829.707
|
| Concept/Terms |
Urinary Bladder Neoplasms- Urinary Bladder Neoplasms
- Neoplasm, Urinary Bladder
- Urinary Bladder Neoplasm
- Neoplasms, Bladder
- Bladder Neoplasms
- Bladder Neoplasm
- Neoplasm, Bladder
- Bladder Tumors
- Bladder Tumor
- Tumor, Bladder
- Tumors, Bladder
Urinary Bladder Cancer- Urinary Bladder Cancer
- Cancer, Urinary Bladder
- Malignant Tumor of Urinary Bladder
- Cancer of the Bladder
- Bladder Cancer
- Bladder Cancers
- Cancer, Bladder
- Cancer of Bladder
|
Below are MeSH descriptors whose meaning is more general than "Urinary Bladder Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Urinary Bladder Neoplasms".
This graph shows the total number of publications written about "Urinary Bladder Neoplasms" by people in this website by year, and whether "Urinary Bladder Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 2 | 0 | 2 | | 2003 | 2 | 1 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 5 | 1 | 6 | | 2007 | 3 | 1 | 4 | | 2008 | 3 | 0 | 3 | | 2009 | 5 | 0 | 5 | | 2010 | 3 | 1 | 4 | | 2011 | 6 | 1 | 7 | | 2012 | 4 | 0 | 4 | | 2013 | 3 | 1 | 4 | | 2014 | 8 | 1 | 9 | | 2015 | 4 | 0 | 4 | | 2016 | 6 | 1 | 7 | | 2017 | 11 | 0 | 11 | | 2018 | 12 | 0 | 12 | | 2019 | 8 | 0 | 8 | | 2020 | 6 | 1 | 7 | | 2021 | 6 | 1 | 7 | | 2022 | 11 | 0 | 11 | | 2023 | 11 | 0 | 11 | | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Urinary Bladder Neoplasms" by people in Profiles.
-
Lerner SP, McConkey DJ, Tangen CM, Meeks JJ, Flaig TW, Hua X, Daneshmand S, Alva AS, Lucia MS, Theodorescu D, Goldkorn A, Milowsky MI, Choi W, Bangs R, Gustafson DL, Plets M, Thompson IM. Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449.
-
Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab. Future Oncol. 2024 Mar; 20(7):351-360.
-
Santoni M, Massari F, Takeshita H, Tapia JC, Dionese M, Pichler R, Rizzo M, Lam ET, Grande E, Kemp R, Molina-Cerrillo J, Calabr? F, Tural D, K?ronya Z, Kucharz J, Fiala O, Seront E, Kopp RM, Abahssain H, Kopecky J, Martignetti A, Kanesvaran R, Zakopoulou R, Ansari J, Landmesser J, Mollica V, Porta C, Bellmunt J, Salah S, Santini D. Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study. Clin Exp Med. 2023 Dec; 23(8):5413-5422.
-
Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Lerner SP. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.
-
Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM, Lerner SP. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 09; 84(3):341-347.
-
Castro-Alonso FJ, Beas-Lozano E, Remolina-Bonilla YA, Flaig TW, Bourlon MT. Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma. Oncology (Williston Park). 2023 06 12; 37(6):256-261.
-
Kukreja JB. Non-muscle-invasive Bladder Cancer: Side-by-Side Guideline Comparison. Eur Urol Focus. 2023 11; 9(6):954-956.
-
Santoni M, Myint ZW, B?ttner T, Takeshita H, Okada Y, Lam ET, Gilbert D, K?ronya Z, Tural D, Pichler R, Grande E, Crabb SJ, Kemp R, Massari F, Scagliarini S, Iacovelli R, Vau N, Basso U, Maruzzo M, Molina-Cerrillo J, Galli L, Bamias A, De Giorgi U, Zucali PA, Rizzo M, Seront E, Popovic L, Caffo O, Buti S, Kanesvaran R, Kopecky J, Kucharz J, Zeppellini A, Fiala O, Landmesser J, Ansari J, Giannatempo P, Rizzo A, Zabalza IO, Monteiro FSM, Battelli N, Calabr? F, Porta C. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. Cancer Immunol Immunother. 2023 Sep; 72(9):2961-2970.
-
de Jong FC, Laajala TD, Hoedemaeker RF, Jordan KR, van der Made ACJ, Boev? ER, van der Schoot DKE, Nieuwkamer B, Janssen EAM, Mahmoudi T, Boormans JL, Theodorescu D, Costello JC, Zuiverloon TCM. Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu?rin. Sci Transl Med. 2023 05 24; 15(697):eabn4118.
-
Warrick JI, Al-Ahmadie H, Berman DM, Black PC, Flaig TW, H?glund M, Bubendorf L, van der Kwast TH, Cheng L. International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility. Am J Surg Pathol. 2024 Jan 01; 48(1):e32-e42.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|